OWC Pharmaceutical Research Corp (OWCP)

[Triple9]

Yes, I think the latest 8-K showed us that they are going to immediately go after the "herbal" market with the addition of Dr. Rozenblat

On February 5, 2017, OWC Pharmaceutical Research Corp. (the "Registrant") appointed Dr. Sharon Rozenblat as a Senior Advisor to the Scientific Advisory Board of the Registrant's wholly-owned Israeli subsidiary, One World Cannabis Ltd ("OWC Israel"). In her capacity as Senior advisor, Dr. Rozenblat will oversee, supervise and bring to fruition the commercial application of OWC Israel's cannabinoid-based medical skin treatment, as she leads the completion of the study of psoriasis, which commenced in November 2016.

Dr. Rozenblat has served as an independent consultant to companied engaged in the field of research and development, principally involving herbal products for the pharmaceutical and raw materials industries. Dr. Rozenblat has also assisted companies in the convergence of science and the commercial exploitation of innovative products based on botanicals.

Dr. Rozenblat has over 15 years of experience in research and development of the study and application of herbal extracts for medical products mainly in the field of dermatology. From 2007 through 2015, Dr. Rozenblat served as the Chief Scientist at Kamedis Ltd., located in Tel Aviv-Yafo, Israel, an herbal-based dermatological company that was founded in 1998 for development of products to treat skin conditions.

But I think you're missing one key point in making the standard comparison to a typical biotech going through the FDA approval process. There is no cost/reward basis for getting FDA approval at this time because no Insurance companies reimburse patients for MMJ purchases. Actually I think I recall some states moving to requiring coverage, but it's a long way off and I'm sure it will be easily challenged by the Insurance co's lawyers as long as cannabis is schedule 1.

I think if you look at $OWCP's pipeline, you can see they made a very smart decision to accelerate the psoriasis cream because they knew that sales could begin in EU, Asia and elsewhere without costly FDA approvals.

I've seen several other MMJ companies with sales in EU, Russia, Asia and South America while initiating FDA trials. It makes a lot of economic sense.